Research programme: antibacterials - Uteron Pharma

Drug Profile

Research programme: antibacterials - Uteron Pharma

Alternative Names: Antivag; Biovag; Vaginate

Latest Information Update: 15 Jul 2015

Price : $50

At a glance

  • Originator Uteron Pharma
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Vaginitis

Most Recent Events

  • 23 Jan 2013 Preclinical trials in Vaginitis in Belgium (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top